MEXAXON-500 MG

Description

MEXAXON-500 MG Injection contains Ceftriaxone 500 mg, a third-generation cephalosporin antibiotic used to treat selected bacterial infections. Ceftriaxone works by interfering with bacterial cell-wall formation, which can stop susceptible bacteria from growing and lead to their destruction.

The product information supplied with the pack lists Gonorrhea, Joint Infections, Meningitis and Septicemia among its benefits. However, the physician should select ceftriaxone according to the suspected or confirmed bacterial infection, patient factors and local antimicrobial susceptibility patterns. Ceftriaxone also remains an important medicine in the management of several serious bacterial infections.

For related pharmaceutical formulations and therapeutic segments, explore the Medhexa Pharma product range.

Therapeutic Segment

Antibiotics | Cephalosporin Antibiotics | Hospital & Critical Care

Uses of MEXAXON-500 MG

MEXAXON-500 MG may help treat selected bacterial infections when a healthcare professional considers ceftriaxone appropriate.

The product information supplied with the pack lists:

• Gonorrhea
• Joint Infections
• Meningitis
• Septicemia

Ceftriaxone can treat infections caused by susceptible bacteria at different body sites. In addition, healthcare professionals may use it for certain respiratory, urinary, bloodstream, abdominal, bone and joint infections depending on the clinical situation and microbiological findings.

For uncomplicated gonorrhea, current CDC guidance recommends ceftriaxone 500 mg by intramuscular injection as a single dose for adults and adolescents weighing less than 150 kg. Patients weighing 150 kg or more require a different dose. Therefore, healthcare professionals should follow the current guideline applicable to the patient and infection rather than using the product strength alone to determine treatment.

Key Benefits of MEXAXON-500 MG

• Contains Ceftriaxone 500 mg, a third-generation cephalosporin antibiotic.
• Provides antibacterial activity against susceptible organisms.
• Supports treatment of selected serious bacterial infections.
• The supplied product information lists gonorrhea, joint infections, meningitis and septicemia among its clinical uses.
• Provides an injectable dosage form for professional medical use.
• Ceftriaxone can achieve useful concentrations in several body tissues and fluids, supporting treatment of appropriately susceptible infections.

How MEXAXON-500 MG Works

MEXAXON-500 MG contains ceftriaxone, which belongs to the cephalosporin group of beta-lactam antibiotics.

First, ceftriaxone reaches susceptible bacteria and interferes with the enzymes involved in bacterial cell-wall synthesis. As a result, bacteria cannot maintain a stable cell wall.

Consequently, susceptible bacteria become damaged and die. However, some bacteria produce beta-lactamase enzymes or develop other resistance mechanisms that can reduce ceftriaxone activity.

Therefore, doctors should consider the suspected organism, culture results and antimicrobial susceptibility when these results are available. Appropriate antibiotic selection also helps support responsible antimicrobial use.

Common Side Effects of MEXAXON-500 MG

Some patients may experience side effects during ceftriaxone treatment, including:

• Pain or discomfort at the injection site
• Diarrhea
• Nausea
• Vomiting
• Headache
• Skin rash
• Changes in liver-related laboratory values

In addition, ceftriaxone can occasionally cause serious allergic reactions or antibiotic-associated diarrhea.

Therefore, patients should promptly seek medical attention if they develop difficulty breathing, facial or throat swelling, severe skin reactions, persistent or severe diarrhea, or other serious symptoms.

Important Safety Information

Prescription and professional use: MEXAXON-500 MG should only be used under the direction of a qualified healthcare professional.

Allergy: Patients with a history of serious hypersensitivity to ceftriaxone, cephalosporins, penicillins or other beta-lactam antibiotics require careful medical assessment before treatment.

Antibiotic resistance: Use ceftriaxone only when a bacterial infection requires antibiotic treatment. Unnecessary antibiotic use can contribute to antimicrobial resistance. Current CDC information highlights ongoing concern about ceftriaxone susceptibility in Neisseria gonorrhoeae.

Gonorrhea: Patients receiving ceftriaxone for gonorrhea should follow current STI treatment guidance. In particular, clinicians should assess whether chlamydial infection has been excluded and manage it according to current recommendations.

Severe diarrhea: Antibiotics can cause Clostridioides difficile-associated diarrhea. Contact a healthcare professional if severe or persistent diarrhea develops during or after treatment.

Gallbladder and biliary effects: Ceftriaxone can sometimes cause biliary sludge or related complications, particularly during certain treatment situations. Inform the treating physician about persistent abdominal pain or other concerning symptoms.

Kidney and liver conditions: Patients with significant kidney or liver problems should inform their doctor before treatment so the healthcare team can assess the appropriate regimen.

Pregnancy and breastfeeding: Patients who are pregnant, planning pregnancy or breastfeeding should tell their healthcare professional before receiving ceftriaxone.

Dosage & Administration

The dosage of MEXAXON-500 MG depends on the type and severity of infection, the patient’s age, body weight, kidney and liver function, and the susceptibility of the causative organism.

A qualified healthcare professional should determine the dose, route and treatment duration.

Do not self-administer MEXAXON-500 MG.

For gonorrhea, current CDC guidance recommends ceftriaxone 500 mg IM as a single dose for persons weighing less than 150 kg, while patients weighing 150 kg or more require 1 g. Other infections, including meningitis and serious bloodstream infections, require different dosing schedules. Therefore, the physician must determine the appropriate regimen for the specific infection.

The healthcare professional should reconstitute and administer the injection according to the manufacturer’s approved instructions and inspect the prepared solution before administration.

Storage

• Store MEXAXON-500 MG according to the storage conditions stated on the manufacturer’s label.
• Protect the vial from unsuitable temperatures, moisture and direct light where applicable.
• Keep the medicine out of reach of children.
• Do not use the product after its expiry date.
• Do not use the vial if the container appears damaged or the powder shows an abnormal appearance.
• Follow the manufacturer’s instructions for reconstitution and use.